Neoadjuvant therapy in rectal cancer—one year follow-up results of standard versus total neoadjuvant strategies
Abstract Background Locally advanced rectal cancer (LARC) poses a significantly challenge in clinical management, requiring a multimodal treatment approach. Among innovative strategies, Total Neoadjuvant Therapy (TNT) has emerged, delivering all planned chemotherapy before surgery. Objective Our aim...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | World Journal of Surgical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12957-024-03590-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850064840267137024 |
|---|---|
| author | Luís Correia Gomes Bernardo Alves Pereira Isália Miguel Ana Luís Ana Pina Cátia Pedro Daniela Cavadas Daniela Pereira Joana Lemos João Maciel João Oliveira José Venâncio Madalena Santos Manuel Limbert Miguel Braga Miriam Abdulrehman Pedro Freitas Ricardo Fonseca Teresa Ferreira Isadora Rosa |
| author_facet | Luís Correia Gomes Bernardo Alves Pereira Isália Miguel Ana Luís Ana Pina Cátia Pedro Daniela Cavadas Daniela Pereira Joana Lemos João Maciel João Oliveira José Venâncio Madalena Santos Manuel Limbert Miguel Braga Miriam Abdulrehman Pedro Freitas Ricardo Fonseca Teresa Ferreira Isadora Rosa |
| author_sort | Luís Correia Gomes |
| collection | DOAJ |
| description | Abstract Background Locally advanced rectal cancer (LARC) poses a significantly challenge in clinical management, requiring a multimodal treatment approach. Among innovative strategies, Total Neoadjuvant Therapy (TNT) has emerged, delivering all planned chemotherapy before surgery. Objective Our aim was to evaluate the real-world application and efficacy of TNT and to compare it with the non-TNT standard strategy. Methods This retrospective study compared locally advanced rectal adenocarcinoma patients treated with Total Neoadjuvant Therapy (TNT) in 2022 with those who underwent traditional chemoradiotherapy (CRT) in 2020–2021. The primary endpoints were the pathologic complete response rate and the sustained clinical complete response rate in patients under W&W. Results Among 107 patients (54.2% male, mean age 62.48 years), non-TNT (67 patients) and TNT (40 patients) mean follow-ups were 26.7 and 8.2 months, respectively. No differences in gender(p = 0.163), staging (p = 0.707), or location (p = 0.727) were noted. TNT patients received more short-course radiotherapy (42.5% vs1.5%, p < 0.001). Clinical responses favored TNT (p = 0.030) with no significant differences in pathological responses, recurrence rates, or survival. TNT exhibited higher chemotherapy completion (p = 0.007) and lower adverse events (p < 0.001). Post-surgery events showed no significant differences (p = 0.470). Single center with retrospective design and carries limitations that may restrict the generalizability of the findings and the relatively short follow-up duration are our main limitations. Conclusion Our data add to the body of literature favoring the TNT treatment strategy for locally advanced rectal cancer, aiming to achieve comparable complete response rates with less adverse events. |
| format | Article |
| id | doaj-art-ddf8bc71bfa64ab58f2bc7f8e934cd35 |
| institution | DOAJ |
| issn | 1477-7819 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMC |
| record_format | Article |
| series | World Journal of Surgical Oncology |
| spelling | doaj-art-ddf8bc71bfa64ab58f2bc7f8e934cd352025-08-20T02:49:09ZengBMCWorld Journal of Surgical Oncology1477-78192024-11-0122111010.1186/s12957-024-03590-4Neoadjuvant therapy in rectal cancer—one year follow-up results of standard versus total neoadjuvant strategiesLuís Correia Gomes0Bernardo Alves Pereira1Isália Miguel2Ana Luís3Ana Pina4Cátia Pedro5Daniela Cavadas6Daniela Pereira7Joana Lemos8João Maciel9João Oliveira10José Venâncio11Madalena Santos12Manuel Limbert13Miguel Braga14Miriam Abdulrehman15Pedro Freitas16Ricardo Fonseca17Teresa Ferreira18Isadora Rosa19Department of Gastroenterology, Portuguese Oncology InstituteDepartment of Oncology, Portuguese Oncology InstituteDepartment of Oncology, Portuguese Oncology InstituteDepartment of Oncology, Portuguese Oncology InstituteDepartment of Oncology, Portuguese Oncology InstituteDepartment of Radiotherapy, Portuguese Oncology InstituteDepartment of General Surgery, Portuguese Oncology InstituteDepartment of Pathology, Portuguese Oncology InstituteDepartment of Gastroenterology, Portuguese Oncology InstituteDepartment of General Surgery, Portuguese Oncology InstituteDepartment of Oncology, Portuguese Oncology InstituteDepartment of Radiology, Portuguese Oncology InstituteDepartment of Oncology, Portuguese Oncology InstituteDepartment of General Surgery, Portuguese Oncology InstituteDepartment of Radiology, Portuguese Oncology InstituteDepartment of Radiotherapy, Portuguese Oncology InstituteDepartment of Oncology, Portuguese Oncology InstituteDepartment of Pathology, Portuguese Oncology InstituteDepartment of Nuclear Medicine, Portuguese Oncology InstituteDepartment of Gastroenterology, Portuguese Oncology InstituteAbstract Background Locally advanced rectal cancer (LARC) poses a significantly challenge in clinical management, requiring a multimodal treatment approach. Among innovative strategies, Total Neoadjuvant Therapy (TNT) has emerged, delivering all planned chemotherapy before surgery. Objective Our aim was to evaluate the real-world application and efficacy of TNT and to compare it with the non-TNT standard strategy. Methods This retrospective study compared locally advanced rectal adenocarcinoma patients treated with Total Neoadjuvant Therapy (TNT) in 2022 with those who underwent traditional chemoradiotherapy (CRT) in 2020–2021. The primary endpoints were the pathologic complete response rate and the sustained clinical complete response rate in patients under W&W. Results Among 107 patients (54.2% male, mean age 62.48 years), non-TNT (67 patients) and TNT (40 patients) mean follow-ups were 26.7 and 8.2 months, respectively. No differences in gender(p = 0.163), staging (p = 0.707), or location (p = 0.727) were noted. TNT patients received more short-course radiotherapy (42.5% vs1.5%, p < 0.001). Clinical responses favored TNT (p = 0.030) with no significant differences in pathological responses, recurrence rates, or survival. TNT exhibited higher chemotherapy completion (p = 0.007) and lower adverse events (p < 0.001). Post-surgery events showed no significant differences (p = 0.470). Single center with retrospective design and carries limitations that may restrict the generalizability of the findings and the relatively short follow-up duration are our main limitations. Conclusion Our data add to the body of literature favoring the TNT treatment strategy for locally advanced rectal cancer, aiming to achieve comparable complete response rates with less adverse events.https://doi.org/10.1186/s12957-024-03590-4Total neoadjuvant therapyLocally advanced rectal cancerChemoradiotherapyComplete clinical responseAdjuvant chemotherapyTreatment completion rates |
| spellingShingle | Luís Correia Gomes Bernardo Alves Pereira Isália Miguel Ana Luís Ana Pina Cátia Pedro Daniela Cavadas Daniela Pereira Joana Lemos João Maciel João Oliveira José Venâncio Madalena Santos Manuel Limbert Miguel Braga Miriam Abdulrehman Pedro Freitas Ricardo Fonseca Teresa Ferreira Isadora Rosa Neoadjuvant therapy in rectal cancer—one year follow-up results of standard versus total neoadjuvant strategies World Journal of Surgical Oncology Total neoadjuvant therapy Locally advanced rectal cancer Chemoradiotherapy Complete clinical response Adjuvant chemotherapy Treatment completion rates |
| title | Neoadjuvant therapy in rectal cancer—one year follow-up results of standard versus total neoadjuvant strategies |
| title_full | Neoadjuvant therapy in rectal cancer—one year follow-up results of standard versus total neoadjuvant strategies |
| title_fullStr | Neoadjuvant therapy in rectal cancer—one year follow-up results of standard versus total neoadjuvant strategies |
| title_full_unstemmed | Neoadjuvant therapy in rectal cancer—one year follow-up results of standard versus total neoadjuvant strategies |
| title_short | Neoadjuvant therapy in rectal cancer—one year follow-up results of standard versus total neoadjuvant strategies |
| title_sort | neoadjuvant therapy in rectal cancer one year follow up results of standard versus total neoadjuvant strategies |
| topic | Total neoadjuvant therapy Locally advanced rectal cancer Chemoradiotherapy Complete clinical response Adjuvant chemotherapy Treatment completion rates |
| url | https://doi.org/10.1186/s12957-024-03590-4 |
| work_keys_str_mv | AT luiscorreiagomes neoadjuvanttherapyinrectalcanceroneyearfollowupresultsofstandardversustotalneoadjuvantstrategies AT bernardoalvespereira neoadjuvanttherapyinrectalcanceroneyearfollowupresultsofstandardversustotalneoadjuvantstrategies AT isaliamiguel neoadjuvanttherapyinrectalcanceroneyearfollowupresultsofstandardversustotalneoadjuvantstrategies AT analuis neoadjuvanttherapyinrectalcanceroneyearfollowupresultsofstandardversustotalneoadjuvantstrategies AT anapina neoadjuvanttherapyinrectalcanceroneyearfollowupresultsofstandardversustotalneoadjuvantstrategies AT catiapedro neoadjuvanttherapyinrectalcanceroneyearfollowupresultsofstandardversustotalneoadjuvantstrategies AT danielacavadas neoadjuvanttherapyinrectalcanceroneyearfollowupresultsofstandardversustotalneoadjuvantstrategies AT danielapereira neoadjuvanttherapyinrectalcanceroneyearfollowupresultsofstandardversustotalneoadjuvantstrategies AT joanalemos neoadjuvanttherapyinrectalcanceroneyearfollowupresultsofstandardversustotalneoadjuvantstrategies AT joaomaciel neoadjuvanttherapyinrectalcanceroneyearfollowupresultsofstandardversustotalneoadjuvantstrategies AT joaooliveira neoadjuvanttherapyinrectalcanceroneyearfollowupresultsofstandardversustotalneoadjuvantstrategies AT josevenancio neoadjuvanttherapyinrectalcanceroneyearfollowupresultsofstandardversustotalneoadjuvantstrategies AT madalenasantos neoadjuvanttherapyinrectalcanceroneyearfollowupresultsofstandardversustotalneoadjuvantstrategies AT manuellimbert neoadjuvanttherapyinrectalcanceroneyearfollowupresultsofstandardversustotalneoadjuvantstrategies AT miguelbraga neoadjuvanttherapyinrectalcanceroneyearfollowupresultsofstandardversustotalneoadjuvantstrategies AT miriamabdulrehman neoadjuvanttherapyinrectalcanceroneyearfollowupresultsofstandardversustotalneoadjuvantstrategies AT pedrofreitas neoadjuvanttherapyinrectalcanceroneyearfollowupresultsofstandardversustotalneoadjuvantstrategies AT ricardofonseca neoadjuvanttherapyinrectalcanceroneyearfollowupresultsofstandardversustotalneoadjuvantstrategies AT teresaferreira neoadjuvanttherapyinrectalcanceroneyearfollowupresultsofstandardversustotalneoadjuvantstrategies AT isadorarosa neoadjuvanttherapyinrectalcanceroneyearfollowupresultsofstandardversustotalneoadjuvantstrategies |